This site is intended for health professionals only!

Published on 2 July 2007

Share this story:
Twitter
LinkedIn
Share
RELATED ARTICLES
Blood pressure drug could combat MS
Novartis confirms growing Gilenya® clinical experience
Bacterial spores – the hidden dangers
UCB announce news of FDA’s complete response letter
Some statistics on COVID-19-related deaths are likely to have been over-reported

Genmab regains lymphoma drug rights

teaser

It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.

Genmab has regained all rights to the HuMax-CD4



Most read

1
Feedback: Automation systems in your hospital
2
Helapet introduce new, improved 20mm Vented Vial Adapter
3
User-friendly osteoporosis therapy launched
4
Merck agrees huge Vioxx settlement
5
Janssen-Cilag’s Stelara approved by NICE



Latest Issue

Read the latest issue >
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
Share this story:
Twitter
LinkedIn
Share
RELATED ARTICLES
NEVO continues to support excellent safety and efficacy outcomes
European Commission approves new twice daily dosing of INCIVO®
An emerging partner? EFPIA offers cost solutions
Positive results for Merck drug
Fruit “can cut drug effectiveness”